ESMO

Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

Monday, September 21, 2020 - 5:45pm

Two-year landmark survival, response, and safety data from this CB-nave cohort were previously presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, held online from September 19-21, 2020.

Key Points: 
  • Two-year landmark survival, response, and safety data from this CB-nave cohort were previously presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, held online from September 19-21, 2020.
  • Provectus' RBD and cGMP RBD manufacturing process are protected by composition of matter and manufacturing patents as well as trade secrets.
  • Patients with at least one injectable lesion and who were candidates for KEYTRUDA were eligible.
  • Information about the Companys clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov .

Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology

Sunday, September 20, 2020 - 1:25pm

Results from SANET-p , in addition to previously presented results from Phase III study of surufatinib in advanced neuroendocrine tumors extra-pancreatic ( SANET-ep ), are published today in The Lancet Oncology.

Key Points: 
  • Results from SANET-p , in addition to previously presented results from Phase III study of surufatinib in advanced neuroendocrine tumors extra-pancreatic ( SANET-ep ), are published today in The Lancet Oncology.
  • Most patients in the trial had Grade 2 disease with heavy tumor burden, including liver metastasis and multiple organ involvement.
  • The positive results of this trial were highlighted in an oral presentation at the 2019 ESMO Congress (clinicaltrials.gov identifier: NCT02588170 ) and published in The Lancet Oncology in September 2020.
  • The results of this study were presented at the ESMO Virtual Congress 2020 and published simultaneously in The Lancet Oncology.

HalioDx contribution to precision medicine at ESMO 2020

Friday, September 18, 2020 - 1:10pm

Jrme Galon in an oral presentation, will offer an update on Colorectal tumour immunology during the Education weekend (Oct. 17, 2020).

Key Points: 
  • Jrme Galon in an oral presentation, will offer an update on Colorectal tumour immunology during the Education weekend (Oct. 17, 2020).
  • We are pleased that recently ESMO recognized the extensive clinical validation of Immunoscore in localised Colon cancer.
  • Beyond that, there is still a lot of indications and therapeutic strategies in which HalioDx can bring to patients and oncologists valuable information to guide cancer care and contribute to precision medicine.
  • Being under the spotlights at main congresses like ESMO 2020 is key for a company innovating in immuno-oncology diagnostics, said Vincent Fert, CEO of HalioDx.

Genetron Health to Highlight Data from 18 Studies at ESMO 2020

Friday, September 18, 2020 - 11:00am

The abstracts include 15 studies on translational medicine covering various cancer types and three studies on bioinformatics development.

Key Points: 
  • The abstracts include 15 studies on translational medicine covering various cancer types and three studies on bioinformatics development.
  • Data that will be highlighted at the ESMO Virtual Congress were generated in collaboration with more than 10 notable cancer centers and clinical hospitals in China.
  • These studies aim at gathering specific data for the Chinese population in order to design precision oncology therapies for the domestic market.
  • We are pleased to showcase our data from 18 research studies at the upcoming ESMO Virtual Congress.

Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO

Friday, September 18, 2020 - 8:00am

Agenus Presentation at ESMO Virtual Congress 2020:

Key Points: 
  • Agenus Presentation at ESMO Virtual Congress 2020:
    Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer.
  • The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs.
  • Agenus is headquartered inLexington, MA.For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio.
  • These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020

Thursday, September 17, 2020 - 2:57pm

Cullinan Pearl, a Cullinan Oncology company, today announced that an abstract detailing the ongoing Phase 1/2a clinical trial evaluating CLN-081 for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC) will be presented as a poster presentation at the ESMO Virtual Congress 2020.

Key Points: 
  • Cullinan Pearl, a Cullinan Oncology company, today announced that an abstract detailing the ongoing Phase 1/2a clinical trial evaluating CLN-081 for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC) will be presented as a poster presentation at the ESMO Virtual Congress 2020.
  • Session Date & Time: From 09:00 Thursday, 17 September 2020 until 20:00 Monday, 21 September 2020.
  • CLN-081 demonstrated acceptable safety, with no dose-limiting toxicities (DLT) and no Grade 3 or greater drug-related adverse events.
  • The most common drug-related adverse events included rash and dry skin, with only one case of Grade 1 drug-related diarrhea being observed.

Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020

Thursday, September 17, 2020 - 1:00pm

The data were made available today in a poster presentation at the European Society of Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • The data were made available today in a poster presentation at the European Society of Medical Oncology (ESMO) Virtual Congress 2020.
  • In addition, BLU-945 was designed to be wild-type EGFR and kinome selective with the potential for improved tolerability and combination strategies.
  • BLU-945 monotherapy resulted in robust anti-tumor activity in multiple cell line-derived and patient-derived xenograft (PDX) models of triple mutant EGFR NSCLC.
  • Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline

Thursday, September 17, 2020 - 8:05am

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • The ARIEL3 data presented in an e-poster reinforce the overall safety profile of Rubraca as a maintenance treatment in patients with recurrent ovarian cancer.
  • Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.
  • Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe.

Amgen To Webcast Investor Calls At ESMO 2020

Wednesday, September 16, 2020 - 9:15pm

THOUSAND OAKS, Calif., Sept. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host two webcast calls for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.

Key Points: 
  • THOUSAND OAKS, Calif., Sept. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host two webcast calls for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.
  • The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com , under Investors.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
  • The webcast will be archived and available for replay for at least 90 days after the event.

Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020

Wednesday, September 16, 2020 - 11:45am

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that members of management will host a virtual investor event following the European Society for Medical Oncology (ESMO) Virtual Congress 2020 where they will highlight select datasets and give an overview of the companys broad oncology portfolio on Sept. 22 at 8:00 am EDT.

Key Points: 
  • Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that members of management will host a virtual investor event following the European Society for Medical Oncology (ESMO) Virtual Congress 2020 where they will highlight select datasets and give an overview of the companys broad oncology portfolio on Sept. 22 at 8:00 am EDT.
  • Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide.
  • At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment.
  • As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types.